Mir-186 inhibits the proliferation and growth of multiple myeloma cells by targeting Jagged-1 expression

被引:1
作者
Dong, Jinfeng [1 ,2 ]
Zheng, Xiaoqiang [1 ,2 ]
机构
[1] Fujian Med Univ, Affiliated Hosp 1, Dept Hematol, Fuzhou 350005, Peoples R China
[2] Fujian Med Univ, Affiliated Hosp 1, Natl Reg Med Ctr, Dept Hematol, Binhai Campus, Fuzhou 350212, Fujian, Peoples R China
关键词
mir-186; Targeted regulation; Jagged1; Inhibition; Multiple myeloma; Multiplication; Growth; CISPLATIN SENSITIVITY; CANCER CELLS; METASTASIS; PROMOTES;
D O I
10.4314/tjpr.v23i1.1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: To investigate the suppressive influence of mir -186 on multiplication and growth of multiple myeloma (MM), as well as the processes involved. Methods: The U266 cells were divided into control, mir -186 overexpression, and inhibition groups. The latter two were transfected with mir -186 agent and antagonist, respectively. Cell viability, colony formation potential, cell cycle ratio, and Jagged-1 mRNA and protein levels were measured using various assays. Results: Cell growth increased over time in all groups. However, mir -186 overexpression cells showed significantly decreased growth and colony formation capacity, relative to control, while the mir -186 inhibition cells showed significantly higher growth and colony formation capacity. The study revealed a higher proportion of G0/G1 stage cells and lower proportion of S-phase cells in mir -186 overexpression cells than in control cells. The opposite effect was seen in mir -186 inhibition cells. Jagged-1 protein and mRNA levels were significantly lower in mir -186 overexpression cells and higher in mir -186 inhibition cells than in control group. The Jagged-1 knockout group showed significantly higher Jagged-1 mRNA and protein levels than both the control and mir -186 overexpression groups (p < 0.05). Conclusion: When overexpressed, mir -186 inhibits the growth of multiple myeloma cells by inhibiting cell colony-formation capacity and by regulating cell cycle through mir-186-induced regulation of the expression of Jagged-1. there is need for more research to confirm the clinical benefits of therapies based on these findings.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 15 条
[1]   RUNX3 regulates hepatocellular carcinoma cell metastasis via targeting miR-186/E-cadherin/EMT pathway [J].
Gou, Yuli ;
Zhai, Fangbing ;
Zhang, Liang ;
Cui, Lan .
ONCOTARGET, 2017, 8 (37) :61475-61486
[2]   Brucine Inhibits Bone Metastasis of Breast Cancer Cells by Suppressing Jagged1/Notch1 Signaling Pathways [J].
Hu Ke-fei ;
Kong Xiang-ying ;
Zhong Mi-cun ;
Wan Hong-ye ;
Lin Na ;
Pei Xiao-hua .
CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2017, 23 (02) :110-116
[3]   MiR-186-5p upregulation inhibits proliferation, metastasis and epithelial-tomesenchymal transition of colorectal cancer cell by targeting ZEB1 [J].
Li, Jinlei ;
Xia, Limin ;
Zhou, Zhenhua ;
Zuo, Zhigui ;
Xu, Chang ;
Song, Huayu ;
Cai, Jianhui .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2018, 640 :53-60
[4]   MORC2 promotes cell growth and metastasis in human cholangiocarcinoma and is negatively regulated by miR-186-5p [J].
Liao, Guanqun ;
Liu, Xiaopeng ;
Wu, Dehai ;
Duan, Fangting ;
Xie, Xueyi ;
Wen, Shunqian ;
Li, Yiqun ;
Li, Shengping .
AGING-US, 2019, 11 (11) :3639-3649
[5]   Jagged1 promotes aromatase inhibitor resistance by modulating tumor-associated macrophage differentiation in breast cancer patients [J].
Liu, Hang ;
Wang, Jingxuan ;
Zhang, Minghui ;
Xuan, Qijia ;
Wang, Zhipeng ;
Lian, Xin ;
Zhang, Qingyuan .
BREAST CANCER RESEARCH AND TREATMENT, 2017, 166 (01) :95-107
[6]   Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma [J].
Richardson, Paul G. ;
Hofmeister, Craig C. ;
Rosenbaum, Cara A. ;
Htut, Myo ;
Vesole, David H. ;
Berdeja, Jesus G. ;
Liedtke, Michaela ;
Chari, Ajai ;
Smith, Stephen D. ;
Lebovic, Daniel ;
Raje, Noopur ;
Byrne, Catriona ;
Liao, Eileen ;
Gupta, Neeraj ;
Di Bacco, Alessandra ;
Estevam, Jose ;
Berg, Deborah ;
Baz, Rachid .
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (02) :231-244
[7]   Emerging immune targets for the treatment of multiple myeloma [J].
Sohail, Atif ;
Mushtaq, Adeela ;
Iftikhar, Ahmad ;
Warraich, Zabih ;
Kurtin, Sandra E. ;
Tenneti, Pavan ;
McBride, Ali ;
Anwer, Faiz .
IMMUNOTHERAPY, 2018, 10 (04) :265-282
[8]   Alteration of miR-186 expression modifies inflammatory markers in normal epithelial and prostate cancer cell models [J].
Suman, Suman ;
Jones-Reed, Dominique Z. ;
Schmidt, M. L. ;
Clark, Geoffrey J. ;
Klinge, Carolyn ;
Barve, Shirish ;
Kimbro, Kevin S. ;
Kidd, La Creis R. .
CANCER RESEARCH, 2017, 77
[9]   Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis [J].
Thoennissen, Gabriela B. ;
Goerlich, Dennis ;
Bacher, Ulrike ;
Aufenberg, Thomas ;
Huesken, Anne-Christin ;
Hansmeier, Anna Antonia ;
Evers, Georg ;
Mikesch, Jan-Henrik ;
Fritz, Fleur ;
Bokemeyer, Carsten ;
Mueller-Tidow, Carsten ;
Stelljes, Matthias ;
Mesters, Rolf M. ;
Krug, Utz ;
Kropff, Martin H. ;
Thoennissen, Nils H. ;
Berdel, Wolfgang E. .
ACTA HAEMATOLOGICA, 2017, 137 (03) :163-172
[10]   A transfer learning approach via procrustes analysis and mean shift for cancer drug sensitivity prediction [J].
Turki, Turki ;
Wei, Zhi ;
Wang, Jason T. L. .
JOURNAL OF BIOINFORMATICS AND COMPUTATIONAL BIOLOGY, 2018, 16 (03)